Stem Cell Therapeutics enrolls first patient in stroke study

By Lisa Kerner

Charlotte, N.C., Sept. 11 - Stem Cell Therapeutics Corp. enrolled the first person in its phase 2a safety study examining the effects of NTx-265, a two-drug therapeutic regimen, in stroke patients.

"This clinical study, which focuses on demonstrating safety and exploring efficacy in human subjects, is also expected to validate the therapeutic approach of drug based therapies designed to harness the potential that exists within a subjects own adult stem cells," chief clinical and regulatory officer Alan Moore said in a news release.

The primary objective of the phase 2a trial is to determine whether the therapy is safe as compared to historical controls, as assessed in terms of adverse events.

Stem Cell Therapeutics is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.